Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
/in International Publications, Newcastle Disease Virus /von 2014-01-06 / Oncoimmunology 2014 Jan;3(1):e27622Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-30Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
/in Dendritic Cells, International Publications /von 2014-01-03 / Cancer Immunol. Immunother. 2014 Apr;63(4):321-33Dendritic cell immunotherapy in uterine cancer
/in Dendritic Cells, Endometrial Cancer, International Publications /von 2014-01-01 / Hum Vaccin Immunother 2014;10(7):1822-7Novel dendritic cell-based vaccination in late stage melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2014-01-01 / Hum Vaccin Immunother 2014;10(11):3132-8Dendritic cell-based vaccines: clinical applications in breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2014-01-01 / Immunotherapy 2014;6(3):349-60Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
/in Colorectal Cancer, Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30Immunotherapy and lung cancer: current developments and novel targeted therapies
/in Dendritic Cells, International Publications, NSCLC /von 2014-01-01 / Immunotherapy 2014;6(11):1221-35Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine
/in Dendritic Cells, International Publications /von 2014-01-01 / Methods Mol. Biol. 2014;1139:17-26
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution